anticoagulation – Medxy AI

Optimizing Extended Apixaban Therapy for Venous Thromboembolism: Insights from Recent Randomized Trials

By MedXY 09/26/2025

Extended low-dose apixaban significantly reduces recurrent venous thromboembolism (VTE) in patients with provoked VTE and enduring risk factors, with minimal major bleeding. Reduced-dose apixaban for cancer-associated VTE is equally effective as full dose but lowers bleeding risk.

Clinical Updates Wellness & Lifestyle

Rivaroxaban vs Warfarin in Postcardiac Surgery Atrial Fibrillation: Insights from the NEW-AF Trial

By MedXY 09/22/2025

The NEW-AF trial compared rivaroxaban and warfarin in new-onset atrial fibrillation after cardiac surgery, finding no difference in length of hospital stay but greater patient convenience and similar safety with rivaroxaban.

Clinical Updates Wellness & Lifestyle

Spontaneous Intramuscular Hematoma in a Patient with Warfarin Therapy: A Case Report

By MedXY 09/04/2025

A 75-year-old male on warfarin presented with spontaneous thigh swelling and pain, diagnosed as spontaneous intramuscular hematoma, successfully managed with supportive care and warfarin reversal.

Clinical Updates Wellness & Lifestyle

Evaluating the Adjuvant Role of Low-Dose Aspirin in Cancer-Associated Venous Thromboembolism: Efficacy, Safety, and Clinical Implications

By MedXY 08/21/2025

Low-dose aspirin added to anticoagulation for cancer-associated VTE reduces recurrence and PE-related mortality but increases bleeding risk, without improving overall survival or net clinical benefit over 6 months.

Clinical Updates Wellness & Lifestyle

Antiplatelet vs Anticoagulant Therapy in Embolic Stroke of Undetermined Source: Insights from a Large Multicenter Cohort Study

By MedXY 08/17/2025

This study found no overall advantage of anticoagulation over antiplatelet therapy in ESUS patients but identified a potential benefit of anticoagulation in those with left ventricular injury.

Clinical Updates Wellness & Lifestyle

Optimizing Anticoagulant Therapy in Frail Elderly AF Patients: Insights from the COMBINE-AF Substudy

By MedXY 08/17/2025

Switching frail, elderly atrial fibrillation patients from warfarin to standard-dose DOAC reduced stroke, fatal and intracranial bleeding, and death, though gastrointestinal bleeding increased. Major bleeding and net clinical outcome remained similar.

Clinical Updates Wellness & Lifestyle

OPTIMAS Trial: Early vs. Delayed Anticoagulation in Acute Ischemic Stroke with Atrial Fibrillation and Chronic Kidney Disease

By MedXY 08/13/2025

The OPTIMAS trial shows that chronic kidney disease does not alter the safety or efficacy of early direct oral anticoagulant use after acute ischemic stroke with atrial fibrillation, supporting early initiation regardless of kidney status.